Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Non Operating Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Non Operating Income for 11 consecutive years, with -$10.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 122.94% to -$10.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.2 million, a 103.42% decrease, with the full-year FY2025 number at -$2.2 million, down 105.0% from a year prior.
  • Other Non Operating Income was -$10.0 million for Q4 2025 at ImmunityBio, down from $49.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $49.2 million in Q3 2025 to a low of -$42.6 million in Q1 2025.
  • A 5-year average of $1.3 million and a median of -$33000.0 in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 26825.0% in 2023, then surged 75792.86% in 2024.
  • ImmunityBio's Other Non Operating Income stood at -$59000.0 in 2021, then plummeted by 216.95% to -$187000.0 in 2022, then plummeted by 19259.89% to -$36.2 million in 2023, then soared by 220.08% to $43.5 million in 2024, then crashed by 122.94% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Non Operating Income are -$10.0 million (Q4 2025), $49.2 million (Q3 2025), and $1.2 million (Q2 2025).